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Introduction 
The use of colonoscopy to diagnose and follow up pat ients 
with inflammatory bowel disease is widely accepted. How­
ever, there is considerable uncertainty as to when colonos­
copy is appropriate with respect to clinical symptoms , re­
sponse to treatment and results of previous investigations. 
Uncertainty is even more important regarding the most ap­
propriate use of colonoscopy in cancer screening in IBD. 
In November 1998, a mult idiscipl inary European expert 
panel convened in Lausanne, Switzerland, to discuss and 
develop criteria for the appropriate use of gastrointestinal 
endoscopy, a widely-used procedure, regarded as highly ac­
curate and safe. The R A N D appropriateness method was 
chosen for this purpose, because it al lows the development 
of appropriateness criteria based on published evidence and 
supplemented by explicit expert opinion. A detailed de­
scription of the R A N D appropriateness method, including 
the literature search process [1] , and of the whole process , 
as well as the global results of the panel [2], are published 
as separate articles in this issue of the Journal . The litera­
ture review was based on a systematic search of Medl ine , 
Embase and the Cochrane Library conducted up to the end 
of 1997 and completed with some key articles publ ished in 
1998. Updat ing and revision of the literature review is cur­
rently ongoing. 
This article presents the literature review on IBD that was 
provided to the panelists for study and commen t prior to 
the panel to support their rat ings of appropriateness of 
colonoscopy in IBD. In addit ion, an overview of the main 
panel results related to IBD and a summary of published 
evidence and panel based appropria teness criteria are 
presented. 
1 . Literature Review 
Introduction 
We found few studies which assessed the impact of colo­
noscopy on patient ou tcome in inf lammatory bowel dis­
ease. Guidel ines developed in 1992 by the Amer ican So­
ciety for Gastrointest inal Endoscopy r e c o m m e n d diagnos­
tic colonoscopy only if the result could favourably influ­
ence initial d iagnosis and management , or for cancer sur­
veil lance. 
Initial Diagnosis and Management of Active Disease 
Ulcerative Colitis 
Colonoscopic visualisation of mucosa l appearance and the 
pattern of disease involvement in the colon in its entirety 
can conf i rm the diagnosis in 8 0 - 9 0 % of cases [3] , with a 
posit ive predict ive value of more than 9 7 % [4]. Total colo­
noscopy is part icularly helpful when there is any doubt 
about the exact nature of the inf lammatory bowel disease 
(i.e. C r o h n ' s Disease, ulcerat ive colit is, microscopic coli­
tis). Ulcerat ive colitis can usually be d iagnosed by means 
of s igmoidoscopy [5], but in some rare cases, however, 
the disease is d iscont inuous with the rectum being spared 
[6]. 
Diagnosis by means of total co lonoscopy is also helpful in 
document ing the extent of the disease, thus providing valu­
able prognostic information. Patients with d iagnosed ul­
cerative pancoli t is show a high proport ion of colectomies 
for uncontrol led disease in the first three years after diag­
nosis [7 ,8 ] . Fur thermore , the disease pattern is not static 
and may evolve over t ime, general ly towards more severe 
disease: one-third of patients with procti t is and 7 0 % of pa­
tients wi th left-sided only colitis at initial d iagnosis showed 
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a progression to pancolitis after initial disease staging [9, 
10]. Major changes in the extent of disease are usually de­
tectable within the first ten years [10]. 
In most instances, disease activity can reliably be moni­
tored using a combination of clinical signs and symptoms 
in conjunction with flexible sigmoidoscopy. The frequency 
and quantity of satisfactory bowel movements correlates 
with the degree of severity of the disease [7,8]. Colonosco­
py permits evaluation of the extent of the disease in those 
cases where proctitis does not respond as expected to a 
course of topical therapy. 
In expert hands, colonoscopy of acute colitis may be safe 
and may serve to select patients with high risk surgical 
complications who need early surgery in case of failure of 
medical treatment [11]. 
Signs of inflammation detected at endoscopy and the clin­
ical symptoms are generally considered to show a strong 
correlation in ulcerative colitis. Procto-sigmoidoscopy thus 
correlated well with patient symptoms in a study evaluating 
the effectiveness of mesalamine as a long-term mainte­
nance therapy [12]. Endoscopic signs of inflammation 
may, however, equally precede clinical symptoms in pa­
tients with as yet clinically inactive colitis [13]. We did 
not find evidence that titration of medication based on en­
doscopic findings resulted in better patient outcome. A 
well-designed prospective randomised clinical trial evaluat­
ed the effect on patient outcome when steroid dose reduc­
tion was correlated to either clinical or endoscopic remis­
sion [14]. One group of patients (clinical and endoscopic 
remission) commenced steroid reduction immediately, and 
a second group (clinical but not endoscopic remission) re­
ceived five additional weeks of steroids prior to dose re­
duction. In this study, no differences were reported in re­
mission rates, numbers of patients successfully weaned of 
steroids, or relapse rate after 18 months. 
Crohn's Disease 
When there is a strong clinical suspicion of Crohn's dis­
ease, colonoscopy up to the terminal ileum with ileal biop­
sies is valuable in confirming or excluding the illness [3, 
4]. Small bowel radiography provides good diagnostic in­
formation in patients with ileal or ileocolic Crohn's dis­
ease. Up to 2 0 % of patients will, however, show normal 
radiographic findings. Crohn's disease patients with ileo­
colic disease more frequently require operative treatment 
and develop more disease-related morbidity (fistulae, ab­
scesses) than those with colitis only [15]. 
Disease activity is at present measured by clinical indices 
[12]. In Crohn's disease, clinical disease activity correlated 
poorly with mucosal lesions and biological activity [16]. In 
the evaluation of the effectiveness of drug therapy, the ma­
jority of authors recommend clinical indices [17,18], while 
others favour endoscopy [19]. For patients who have 
reached clinical remission, adjustment of steroid treatment 
on the basis of colonoscopic findings does not result in ad­
ded benefit, compared to the use of clinical symptoms 
alone [14]. 
Initial Screening for Cancer in Patients with IBD 
Ulcerative Colitis 
Epidemiology. Ulcerative colitis patients have a 20-fold 
increase in risk of the development of colorectal cancer in 
comparison to age- and gender-matched control patients 
[20]. The extent and duration of disease at diagnosis are 
the major determinants of the magnitude of this increased 
risk: the relative risk is highest in patients with pancolitis 
(14.8), less for patients with left-sided colitis (2.8), and 
lowest for patients with proctitis (1.7) [21]. The absolute 
risk for developing colorectal cancer in patients with pan­
colitis is 5 - 1 0 % after 20 years', 7 - 1 4 % after 25 years' 
and 3 0 - 4 0 % after 35 years' duration [22,23]. Age at onset 
of disease is an important variable for cancer risk both for 
left-sided colitis and pancolitis (SIR, standardised inci­
dence ratios) [21] (Table 1). 
Table 1 Colorectal cancer risk according to age at onset of disease 
and extension of colitis (adapted f rom Ebkom et al. 1990) [21 ] 
Age at onset Left-sided colitis Pancolitis 
of disease 
1 5 - 2 9 14.2 (5 .7 - 29.3) 33.1 (18 .1 -55 .5 ) 
3 0 - 3 9 3.5 ( 0 . 7 - 10.2) 17.8 (8.5-32.7) 
4 0 - 4 9 1.9 (0 .2 - 6.7) 12.5 (6 .4-21.7) 
> 5 0 1.3 (0 .4 - 3.1) 
-
5 0 - 5 9 
-
8.1 (3 .3-16.7) 
> 6 0 
-
6.0 (2 .7 -11 .4 ) 
Dysplasia. Dysplastic changes are considered to be predic­
tive of colorectal cancer in ulcerative colitis patients. 
Multicentric tumours can occur in the area of chronic in­
flammation [24]. A recent review of ten prospective studies 
showed that 12% of patients with UC had cancer or dys­
plasia at the initial surveillance examination [22]. Low-
grade dysplasia is predictive of high-grade dysplasia or 
cancer. Long-term follow-up studies showed that the pre­
dictive value of low-grade dysplasia was 3 5 % for high-
grade dysplasia [25], and 54% for high-grade dysplasia or 
cancer [26]. There are, however, several problems related 
to the question of dysplasia: firstly, the diagnosis of low-
grade dysplasia is subject to gross inter-observer error 
[27]: inter-observer agreement on the grade of dysplasia is 
poor, ranging from 42 to 72% [28,29]. Secondly, the pro­
portion of cancers arising from a background of colitis and 
occurring without a detectable phase of dysplasia may be 
as high as 2 5 % [30 ] -50% [23,31-33] Thirdly, some stud­
ies have shown that low-grade dysplasia is not predictive 
of the development of colorectal cancer in the absence of 
a mass lesion [22,33]. 
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Surveillance. Surveillance strategy is based on the as­
sumption that dysplastic lesions can be detected before in­
vasive cancer has developed [22]. Most of the data stem 
from studies investigating variations in sampling protocols 
and different clinical approaches in patients with indeter­
minate, low- and high-grade dysplasia in the context of 
surveillance programmes [31-34] . There is some low-
strength evidence that surveillance programmes do indeed 
improve patient outcome. A retrospective study [35] found 
that patients undergoing surveillance had cancer detected 
at an earlier stage than patients who were not followed up, 
resulting in a significant improvement in the five-year sur­
vival rate (77% compared to 36%). Colonoscopic surveil­
lance for dysplasia in ulcerative colitis patients is recom­
mended as an alternative to prophylactic colectomy, in 
particular in patients with total ulcerative colitis, and sur­
veillance should begin seven to ten years after diagnosis 
[32.36-39]. The optimum interval between surveillance 
colonoscopies is not clear, but could most probably be in 
excess of one year when the first control colonoscopy is 
negative [22]. Multiple biopsies should be carried out dur­
ing the same colonoscopy [24]. In conclusion, the literature 
data support surveillance, while at the same time recognis­
ing its limitations [31,33,40-42]. 
Patient compliance is a major determinant which limits the 
effectiveness of surveillance programmes in ulcerative co­
litis patients [25,26,31,32,34,42]. The question of the 
cost-effectiveness of surveillance programmes is still being 
studied [31,32]. In a large prospective surveillance study in 
160 patients with long-standing and extensive ulcerative 
colitis, representing a total of 739 colonoscopies (per­
formed between 1978 and 1990) and 709 patient years of 
follow-up, only one out of a total of nine colitis-related 
cancers was detected by the surveillance programme, thus 
casting some doubt on its effectiveness [43]. In contrast, a 
retrospective review of 248 patients with extensive ulcera­
tive colitis (mean duration of disease 12 years) detected 
seven patients with cancer, six of whom were identified at 
colonoscopy, and one patient with negative visual endo­
scopic findings was discovered by means of surveillance 
biopsies. It is too early to evaluate the benefit of alterna­
tive techniques such as DNA aneuploidy and biopsies [24, 
36]. 
Crohn's disease. Patients with Crohn's disease have an es­
timated six-fold increase in risk of bowel cancer compared 
to the general population [30,44]. This relative risk is sim­
ilar to the risk for patients with left-sided ulcerative colitis 
in a referral-based strategy [20]. When Crohn's patients 
with long-standing colitis or ileitis also show dysplastic 
changes [45 -47], the risk of carcinoma is particularly high 
in those loops of bowel bypassed at operation and in long­
standing fistulae [47]; and the risk is higher in patients 
who were less than 30 years old at diagnosis (relative risk 
20.9), compared to patients for whom the diagnosis of 
Crohn's disease was made at a later age (relative risk 
2.2). Incidence of small bowel cancer is significantly in­
creased in Crohn's disease (relative risk 86 in ileocolitis, 
115 in regional enteritis) [20]. The average time from onset 
of Crohn's disease to diagnosis of carcinoma is about 16 
years: these patients may therefore benefit from periodic 
screening beginning after this interval of time. However, 
for the time being, there is no unequivocal evidence that 
surveillance of patients with Crohn's disease results in im­
proved outcome with respect to colorectal cancer. 
2. Panel Results 
The experts of the European panel on appropriateness of 
gastrointestinal endoscopy (EPAGE) considered the above 
literature review as well as their own clinical expertise in 
evaluating the appropriateness of colonoscopy for inflam­
matory bowel disease (IBD). Definitions of terms, clinical 
variables used, general and specific panel results related to 
IBD are presented. 
Definition of Terms 
Table 2 shows the definitions used by the European expert 
panel on gastrointestinal endoscopy to assess appropriate­
ness of colonoscopy for IBD. 
Table 2 Definitions used by the European expert panel on gastro­
intestinal endoscopy to assess appropriateness of colonoscopy for 
IBD 
Ulcerative colitis 
Documented by one or more of the fo l lowing: endoscopic 
appearance, mucosal biopsy, operative report w i th pathology 
and infectious cause excluded. 
Crohn's disease 
Documented by one or more of the fo l lowing: endoscopic 
appearance, mucosal biopsy, radiography, operative report w i th 
pathology and infectious cause excluded. 
Extension of IBD 
Evaluation of the extension of the disease (proctitis, pancolitis, 
left-sided colitis) w i th no previous colonoscopy done. 
Lower Gl evaluation 
Sigmoidoscopy or SBFT (small bowel fo l low-through) performed 
within the last 3 months and since symptoms began, recurred or 
worsened. Sigmoidoscopy: flexible tube (60 cm). 
Low-grade dysplasia 
Low degree of a combination of architectural and cytological 
alterations such as gross distort ion, hyperchromasia, enlarged 
nuclei, large nucleoli, loss of cellular polarity confirmed wi th in 
the basement membrane of the glands in which it arose. 
High-grade dysplasia 
High degree of a combination of architectural and cytological 
alterations such as gross distortion, hyperchromasia, enlarged 
nuclei, large nucleoli, loss of cellular polarity confirmed wi th in 
the basement membrane of the glands in which it arose. 
Therapy 
Daily treatment for at least 14 days w i th one or more of the 
fo l lowing: 5-ASA (enema, suppositories or oral), sulfasalazine, 
topical steroids or daily prednisone for at least 2 weeks or alter­
nate day prednisone for at least 4 weeks or daily treatment 
wi th one of the fo l lowing for at least 60 days: azathioprine, 
cyclosporine, 6-MP. 
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Clinical Variables 
The clinical variables and their levels of detail that were 
used to create and rate patient scenarios to assess the ap­
propriateness of use of co lonoscopy in pat ients with known 
I B D are listed in Table 3 a and in Table 3 b for cancer 
screening in IBD. 
Table 3a Clinical variables used in inf lammatory bowel disease 
(UC: ulcerative colitis, CD: Crohn's disease) 
Variables Number of Categories 
categories 
IBD 3 - known UC 
- known CD wi thout colitis 
- known CD wi th colitis 
Therapy 2 - no therapy 
- current therapy 
Symptoms 2 - symptoms absent or 
improved 
- symptoms unimproved 
or worse 
Evaluation of the ex­ 2 - evaluation of CD 
tension of IBD no - evaluation of UC 
previous colonoscopy 
Evaluation done 
- for UC 3 - no recent sigmoidoscopy 
- normal sigmoidoscopy 
- active disease at sigmo­
idoscopy 
- for UD 3 - no recent SBFT 
- normal SBFT 
- active disease at SBFT 
Table 3b Clinical variables for cancer screening in patients w i th 
known IBD 
Variables Number of Categories 
categories 
Data of last screening 
colonoscopy 
- for UC 3 - no index colonoscopy 
- < 2 years ago 
- > 2 years ago 
- for CD 3 - no index colonoscopy 
- < 3 years ago 
- > 3 years ago 
Extension of IBD* 
- for UC 3 - UC proctitis 
- UC left-sided colitis 
- UC pancolitis 
- for CD 2 - w i thout colitis 
- w i th colitis 
Result of last biopsy 7 - dysplasia never detected 
- low-grade dysplasia 
Time since disease 3 - < 8 years 
onset - 8 - 1 5 years 
- > 1 5 years 
* diagnosis at last colonoscopy 
General Panel Results 
I B D was assessed in 59 clinical scenarios stratified into 4 
categories : Evaluation of known U C ( 1 3 i tems), evaluation 
of known C D (17 i tems), screening for colorectal cancer in 
patients with known U C (19 items) and screening for colo­
rectal cancer in pat ients with known C D (10 items). Of the 
59 scenarios, 24 ( 4 1 % ) were rated appropriate, 10 (17%) 
uncertain and 25 ( 4 2 % ) inappropriate. The rate of overall 
agreement of panelists for these scenarios was 5 6 % . 
Specific Clinical Panel Results 
The main results for the appropriateness of colonoscopy in 
I B D are worded as overall s tatements representing several 
clinical scenarios. In some cases, because of the matrix­
like nature of scenario development , the same scenario 
may be included in more than one statement. Forty-two of 
the 59 indicat ions (71 % ) could be characterized by the 11 
overall s ta tements in Tables 4 a and 4 b. Detailed appropri­
ateness and necessi ty criteria on the appropriate or crucial 
nature of colonoscopy, including voting distributions of pa­
nelists, are available in a computer ized form, accessible via 
Internet at the EPAGE web site (http:/ /www.epage.ch). 
Description of Appropriateness 
Appropr ia teness of use of colonoscopy is described in Ta­
ble 3 a for known I B D and in Table 4 b for cancer screen­
ing in IBD. 
Description of Necessity 
Ten out of 59 scenarios ( 1 7 % ) related to IBD were judged 
necessary. Necessary indications are summarized by 3 
s ta tements in Table 5 and pertained exclusively to cancer 
screening in IBD patients. In some cases, the same scenar­
io may apply to more than one statement. 
3. Conclusions 
Colonoscopy reliably assesses the type, extension and evo­
lution of inf lammatory bowel disease ( IBD). In Crohn ' s 
disease, small bowel disease may be evaluated by a small 
bowel follow-through (SBFT) . Risk of colorectal cancer in­
creases with extent and duration of the disease, particularly 
in UC. Though the impor tance of dysplasia as a precancer­
ous lesion is recognized, there is only very limited evi­
dence that surveil lance p rogrammes do indeed improve pa­
tient ou tcome. In addit ion, the op t imum interval in which 
screening colonoscopy has to be performed remains un­
clear. 
In IBD, 4 2 % of the clinical scenarios were judged to be 
inappropriate indicat ions for colonoscopy. Seventeen per­
cent of clinical scenarios were judged necessary, all of 
which dealt with colorectal cancer screening in IBD pa­
tients. Seventy-eight percent of the scenarios could be en­
compassed in 12 descript ive clinical s tatements. The de-
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Table 4 a Description of appropriateness of indications for colo­
noscopy for known IBD 
Clinical situations 
In individuals wi th known ulcerative colitis of Crohn's disease 
wi th no previous colonoscopy, indication for colonoscopy is 
appropriate to evaluate the extension of disease 
In individuals wi th known ulcerative colitis of Crohn's disease 
wi th improved or no symptoms, w i th or w i thout current therapy, 
indication for colonoscopy is 
inappropriate 
In individuals wi th known ulcerative colitis w i th unimproved 
or worsened symptoms wi thout current therapy, indication for 
colonoscopy is 
generally appropriate 
In individuals wi th known Crohn's disease w i th unimproved or 
worsened symptoms, wi th or wi thout current therapy, and normal 
SBFT, indication for colonoscopy is 
generally appropriate 
In individuals w i th known Crohn's disease w i th unimproved 
or worsened symptoms wi thout current therapy, indication for 
colonoscopy is 
generally uncertain 
In individuals wi th known Crohn's disease w i th unimproved 
or worsened symptoms wi thout therapy, indication for colonos­
copy is 
generally inappropriate 
Table 4 b Description of appropriateness of indications for colo­
noscopy for cancer screening in IBD 
Clinical situations 
In individuals wi th known ulcerative colitis, indication for colo­
noscopy is 
generally appropriate if an index endoscopy has never been 
done 
In individuals wi th known ulcerative colitis w h o had a colonoscopy 
2 years or less previously, indication for colonoscopy is 
generally inappropriate 
In individuals wi th known ulcerative colitis or Crohn's disease 
for > 1 5 years, indication for colonoscopy is 
appropriate if interval since last screening endoscopy is: 
ulcerative colitis > 2 years 
Crohn's disease > 3 years 
In individuals wi th known ulcerative colitis or Crohn's disease 
wi th low-grade dysplasia, indication for colonoscopy is 
appropriate 
In individuals wi th known ulcerative colitis l imited to proctitis 
or wi th Crohn's disease wi thout colonic involvement, indication 
for colonoscopy is 
inappropriate 
tailed and specific character of these criteria are best re­
vealed in the computer ized form available on the Internet 
(http:/ /www.epage.ch). 
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